Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

Blood test may spot hidden artery risk in dialysis patients

NCT ID NCT07179211

Knowledge-focused Sponsor: Sohag University Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing This study
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 26, 2026 · Last updated Jun 26, 2026

Summary

This study looks at 120 adults on regular hemodialysis to see if a simple blood test called the neutrophil-to-lymphocyte ratio (NLR) can help detect peripheral artery disease (PAD). PAD is a common but often overlooked complication in kidney patients. The goal is to find a cheap, easy way to identify those at higher risk, so they can get help sooner.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

What this could lead to
If successful, this could lead to a simple, low-cost blood test to help identify hemodialysis patients at risk for peripheral artery disease, allowing for earlier monitoring and care.
What could go wrong
This is an observational study, not a treatment trial. It only looks for a link between a blood marker and disease, so it won't directly improve health. The results may not apply to all patient groups.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Participants

About 120 people

The number the study aims to enrol. It can still change while the study runs.

Started

Jul 2025

Expected to finish

Jul 2026

An estimate. End dates often move.

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Who is studied

The present study aims to investigate the relationship between NLR and the presence of PAD in patients undergoing regular hemodialysis. By establishing this association in a well-defined population, we hope to provide evidence that supports the use of NLR as a simple, cost-effective tool for PAD risk stratification and early intervention

Ages

Children (under 18), adults (18 to 64) and older adults (65 and over)

Sex

Anyone

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Adult patients aged ≥18 years. * Undergoing maintenance hemodialysis for at least 3 months (thrice weekly) * Able to provide informed consent. * Willing to undergo clinical and laboratory evaluations, including peripheral vascular assesment Exclusion Criteria: * Active infection or sepsis at the time of evaluation .\* Patients who have a sedimentation rate of more than 60 mm/hour \*. Known autoimmune or hematologic disorders that may influence leukocyte count. * Current use of immunosuppressive therapy, corticosteroids, or chemotherapy.5. History of malignancy.6. Patients with incomplete medical records or unable to undergo peripheral vascular assessment.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Chronic kidney disease are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

chronic kidney disease chronic renal failure syndrome

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Chronic kidney disease

Contacts and locations

Locations

  • Sohag faculty

    Sohag, Egypt

More trials for these conditions

Other studies related to the condition(s) this trial covers.